National Webinar on Biologics & Biosimilars: Insights for Patients & Physicians

Tuesday, August 18, 2020 at 12:00-1:30 p.m. (Eastern)

 

Join AARDA and the Biosimilars Forum for “Biologics & Biosimilars: Insights for Patients and Physicians”. This webinar is designed for those interested in learning more about these medicines made from living organisms used to treat autoimmune disorders and many other diseases. Along with our featured speakers from the FDA, physicians, patients, and other key experts will also address key issues related to biologics and biosimilars.

 

 

Featured Speakers

 

Sarah Yim, MD, Director of the Office of Therapeutic Biologics and Biosimilars, CDER’s Office of New Drugs, FDA

Prior to joining the FDA, Dr. Yim spent 2 years as Director of the Division of Clinical Review in the Office of Generic Drugs, and 11 years in various roles in rheumatology drug review in OND. She received her undergraduate degree from Stanford University, her Doctor of Medicine degree from the Uniformed Services University of Health Sciences, and completed a postdoctoral fellowship in rheumatology at the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), at the National Institutes of Health.

 

 

Emanuela Lacana, PhD, Deputy Director of of the Office of Therapeutic Biologics and Biosimilars, CDER’s Office of New Drugs, FDA

Prior to joining the FDA, Dr. Yim spent 2 years as Director of the Division of Clinical Review in the Office of Generic Drugs, and 11 years in various roles in rheumatology drug review in OND. She received her undergraduate degree from Stanford University, her Doctor of Medicine degree from the Uniformed Services University of Health Sciences, and completed a postdoctoral fellowship in rheumatology at the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), at the National Institutes of Health.

 

 

Jonathan Kay, MD, Professor of Medicine and Population and Quantitative Health Sciences, University of Massachusetts Medical School

Jonathan Kay, MD, is Professor of Medicine and Population and Quantitative Health Sciences and holds the Timothy S. and Elaine L. Peterson Chair in Rheumatology at the University of Massachusetts Medical School in Worcester, where he directs Clinical Research in the Division of Rheumatology. He received his medical degree from the University of California School of Medicine in San Francisco, California. He then completed an internship and residency at the Hospital of the University of Pennsylvania in Philadelphia and fellowships in rheumatology and immunology at the Brigham and Women’s Hospital and Harvard Medical School in Boston, Massachusetts. Over the past decade, he has been involved in the development of biosimilars to treat rheumatic diseases. Dr. Kay lectures internationally and is the author of more than 230 publications and book chapters.

Moderator

 

Randall Rutta, President & CEO, American Autoimmune Related Diseases Association (AARDA)

Mr. Rutta is President & CEO of the American Autoimmune Related Disease Association (AARDA), a national organization dedicated to addressing the problem of autoimmunity, the major cause of more than 100 serious chronic diseases. AARDA initiated and hosts the 40+-member National Coalition of Autoimmune Patient Groups and is a longtime member of the National Health Council. Prior to stepping into his current role on October 1, 2019, he served as AARDA’s Federal Policy Consultant since March 2018. Mr. Rutta has had a decades-long career in health policy and the promotion of health services delivery focusing on vulnerable populations, including people with disabilities, chronic conditions, age-related impairments, and veterans with challenges related to their service.

Co-Sponsor

 

Juliana Reed, MS, President, Biosimilars Forum; Vice President, Corporate Affairs, Global & Biosimilars Lead, Pfizer 

Juliana Reed is the Vice President, Corporate Affairs, for the Pfizer global Immunology, Inflammation and Biosimilars business. Ms. Reed has been engaged in global biosimilar policy for over 15 years through her current position as well as her previous work as Vice President of Global Government Affairs for Hospira, Inc. Ms. Reed has direct pre and post approval market experience in multiple countries across at least 9 biosimilars on the market today. In addition to her corporate positions, Ms. Reed has previously served on the board of the Generic Drug Association in the US, the board of Medicines for Europe, and was a co-founder of the US Biosimilars Forum where she is currently serving as the Forum’s President.